期刊
DRUG METABOLISM REVIEWS
卷 50, 期 4, 页码 466-481出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/03602532.2018.1559184
关键词
Metabolomics; isoniazid; rifampicin; pyrazinamide; ethambutol; pharmacometabonomics; drug metabolism; drug action; drug-resistance
The World Health Organization recommends the directly observed therapy short-course (DOTS) regimen, a combination of four first-line antibiotics (isoniazid, rifampicin, pyrazinamide and ethambutol), for the treatment of active pulmonary tuberculosis (TB). However, despite the fact that this treatment regimen is commonly used worldwide, the metabolism and anti-bacterial mechanisms of these drugs are not yet fully understood. This lack of information ultimately contributes to the poor patient compliance and the subsequent treatment failure and post treatment relapse seen in some TB patients. Pharmacometabonomics, the latest addition to the omics research domain, focuses on the identification of drug-induced metabolome variations. The observed metabolite changes can be used to better understand drug metabolism, drug action and drug-resistance mechanisms. In this review, we summarize the generally known biological mechanisms of the first-line TB drugs included in the DOTS program, and we additionally elaborate on the contribution that pharmacometabonomics has made to the expansion of this knowledge.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据